Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma.

Balis FM, Busch CM, Desai AV, Hibbitts E, Naranjo A, Bagatell R, Irwin M, Fox E.

Pediatr Blood Cancer. 2020 Jan;67(1):e28031. doi: 10.1002/pbc.28031. Epub 2019 Oct 14.

PMID:
31612589
2.

Unrealistic parental expectations for cure in poor-prognosis childhood cancer.

Mack JW, Cronin AM, Uno H, Shusterman S, Twist CJ, Bagatell R, Rosenberg A, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park J, Cohn SL, Levine A, Taddei S, Diller LR.

Cancer. 2020 Jan 15;126(2):416-424. doi: 10.1002/cncr.32553. Epub 2019 Oct 4.

PMID:
31584705
3.

Tandem Transplant for High-Risk Neuroblastoma: Next Steps in the Era of Precision Medicine.

Bagatell R, Irwin MS.

JAMA. 2019 Aug 27;322(8):729-731. doi: 10.1001/jama.2019.11641. No abstract available.

PMID:
31454025
4.

Sclerosing Epithelioid Fibrosarcoma of the Bone With Rare EWSR1-CREB3L3 Translocation Driving Upregulation of the PI3K/mTOR Signaling Pathway.

Shenoy A, Surrey L, Jain P, Foster J, Straka J, Resnick A, Waanders A, Luo M, Li M, Kazahaya K, Bagatell R, Wojcik J, Pogoriler J.

Pediatr Dev Pathol. 2019 Nov-Dec;22(6):594-598. doi: 10.1177/1093526619864230. Epub 2019 Jul 23.

PMID:
31335288
5.

Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers.

Chang F, Lin F, Cao K, Surrey LF, Aplenc R, Bagatell R, Resnick AC, Santi M, Storm PB, Tasian SK, Waanders AJ, Hunger SP, Li MM.

J Mol Diagn. 2019 Sep;21(5):873-883. doi: 10.1016/j.jmoldx.2019.05.006. Epub 2019 Jun 27.

PMID:
31255796
6.

Clinical utility of custom-designed NGS panel testing in pediatric tumors.

Surrey LF, MacFarland SP, Chang F, Cao K, Rathi KS, Akgumus GT, Gallo D, Lin F, Gleason A, Raman P, Aplenc R, Bagatell R, Minturn J, Mosse Y, Santi M, Tasian SK, Waanders AJ, Sarmady M, Maris JM, Hunger SP, Li MM.

Genome Med. 2019 May 28;11(1):32. doi: 10.1186/s13073-019-0644-8.

7.

Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.

Campbell K, Shyr D, Bagatell R, Fischer M, Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, London WB, DuBois SG.

Pediatr Blood Cancer. 2019 Aug;66(8):e27819. doi: 10.1002/pbc.27819. Epub 2019 May 21.

PMID:
31115156
8.

Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.

Miller TP, Fisher BT, Getz KD, Sack L, Razzaghi H, Seif AE, Bagatell R, Adamson PC, Aplenc R.

Pediatr Blood Cancer. 2019 Jul;66(7):e27747. doi: 10.1002/pbc.27747. Epub 2019 Apr 9.

PMID:
30968531
9.

Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).

Pinto N, Naranjo A, Hibbitts E, Kreissman SG, Granger MM, Irwin MS, Bagatell R, London WB, Greengard EG, Park JR, DuBois SG.

Eur J Cancer. 2019 May;112:66-79. doi: 10.1016/j.ejca.2019.02.003. Epub 2019 Apr 1.

PMID:
30947024
10.

Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma.

Hill-Kayser CE, Tochner Z, Li Y, Kurtz G, Lustig RA, James P, Balamuth N, Womer R, Mattei P, Grupp S, Mosse YP, Maris JM, Bagatell R.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):401-408. doi: 10.1016/j.ijrobp.2019.01.095. Epub 2019 Feb 7.

PMID:
30738983
11.

Advances in neuroblastoma therapy.

MacFarland S, Bagatell R.

Curr Opin Pediatr. 2019 Feb;31(1):14-20. doi: 10.1097/MOP.0000000000000711.

PMID:
30480556
12.

The challenge of defining "ultra-high-risk" neuroblastoma.

Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, London WB, Irwin MS.

Pediatr Blood Cancer. 2019 Apr;66(4):e27556. doi: 10.1002/pbc.27556. Epub 2018 Nov 26. Review.

PMID:
30479064
13.

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A.

Clin Cancer Res. 2018 Dec 15;24(24):6142-6149. doi: 10.1158/1078-0432.CCR-18-1381. Epub 2018 Aug 9.

14.

Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.

Desai AV, Li Y, Getz K, Seif AE, Fisher B, Huang V, Aplenc R, Bagatell R.

Pediatr Blood Cancer. 2018 Dec;65(12):e27372. doi: 10.1002/pbc.27372. Epub 2018 Aug 1.

PMID:
30070014
15.

Diagnosis of Beckwith-Wiedemann syndrome in children presenting with Wilms tumor.

MacFarland SP, Duffy KA, Bhatti TR, Bagatell R, Balamuth NJ, Brodeur GM, Ganguly A, Mattei PA, Surrey LF, Balis FM, Kalish JM.

Pediatr Blood Cancer. 2018 Oct;65(10):e27296. doi: 10.1002/pbc.27296. Epub 2018 Jun 22.

16.

Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia.

Fitzgerald JC, Li Y, Fisher BT, Huang YS, Miller TP, Bagatell R, Seif AE, Aplenc R, Thomas NJ.

Pediatr Crit Care Med. 2018 Jun;19(6):e312-e320. doi: 10.1097/PCC.0000000000001525.

17.
18.

Proton therapy for pediatric head and neck malignancies.

Vogel J, Both S, Kirk M, Chao HH, Bagatell R, Li Y, Womer R, Balamuth N, Reilly A, Kurtz G, Lustig R, Tochner Z, Hill-Kayser C.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26858. Epub 2017 Oct 23.

PMID:
29058370
19.

Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR.

Cancer. 2017 Dec 15;123(24):4914-4923. doi: 10.1002/cncr.30934. Epub 2017 Sep 8. Review.

20.

VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.

Setty BA, Stanek JR, Mascarenhas L, Miller A, Bagatell R, Okcu F, Nicholls L, Lysecki D, Gupta AA.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26728. Epub 2017 Jul 27.

PMID:
28748602
21.

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG.

Cancer. 2017 Nov 1;123(21):4224-4235. doi: 10.1002/cncr.30873. Epub 2017 Jul 11.

22.

Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Miller TP, Li Y, Kavcic M, Getz KD, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves MH, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R.

Haematologica. 2017 Sep;102(9):e340-e343. doi: 10.3324/haematol.2017.168815. Epub 2017 Jun 22. No abstract available.

23.

Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R.

Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23.

24.

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D.

J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. Review.

25.

Refining megatherapy, improving outcome in neuroblastoma.

Bagatell R, Grupp SA.

Lancet Oncol. 2017 Apr;18(4):423-424. doi: 10.1016/S1470-2045(17)30069-4. Epub 2017 Mar 2. No abstract available.

PMID:
28259607
26.

Using electronic medical record data to report laboratory adverse events.

Miller TP, Li Y, Getz KD, Dudley J, Burrows E, Pennington J, Ibrahimova A, Fisher BT, Bagatell R, Seif AE, Grundmeier R, Aplenc R.

Br J Haematol. 2017 Apr;177(2):283-286. doi: 10.1111/bjh.14538. Epub 2017 Feb 1.

27.

Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation.

Li R, Polishchuk A, DuBois S, Hawkins R, Lee SW, Bagatell R, Shusterman S, Hill-Kayser C, Al-Sayegh H, Diller L, Haas-Kogan DA, Matthay KK, London WB, Marcus KJ.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):270-277. doi: 10.1016/j.ijrobp.2016.10.047. Epub 2016 Nov 8.

PMID:
28068235
28.

The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia.

Winestone LE, Getz KD, Miller TP, Wilkes JJ, Sack L, Li Y, Huang YS, Seif AE, Bagatell R, Fisher BT, Epstein AJ, Aplenc R.

Am J Hematol. 2017 Feb;92(2):141-148. doi: 10.1002/ajh.24605. Epub 2016 Dec 7.

29.

Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals.

Rao P, Li Y, Getz KD, Miller TP, Huang YS, Wilkes JJ, Seif AE, Bagatell R, Fisher BT, Gracia C, Aplenc R.

Cancer. 2016 Nov 15;122(21):3394-3400. doi: 10.1002/cncr.30225. Epub 2016 Sep 12.

30.

Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report.

Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Alonzo T, Gerbing R, Sung L, Hall M, Bagatell R, Gamis A, Fisher BT, Aplenc R.

Cancer Med. 2016 Sep;5(9):2412-6. doi: 10.1002/cam4.839. Epub 2016 Jul 29.

31.

Volume-Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy.

Wilkes JJ, Hennessy S, Xiao R, Rheingold S, Seif AE, Huang YS, Vendetti N, Li Y, Bagatell R, Aplenc R, Fisher BT.

Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):404-410.e1. doi: 10.1016/j.clml.2016.04.016. Epub 2016 May 4.

32.

The Beginning of the End of Package Deal Therapy for Patients With High-Risk Neuroblastoma?

Barrett DM, Bagatell R.

J Clin Oncol. 2016 Jul 20;34(21):2437-9. doi: 10.1200/JCO.2016.67.2774. Epub 2016 May 9. No abstract available.

PMID:
27161969
33.

Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States.

Salazar EG, Li Y, Fisher BT, Rheingold SR, Fitzgerald J, Seif AE, Huang YS, Bagatell R, Aplenc R.

Br J Haematol. 2016 Aug;174(4):591-9. doi: 10.1111/bjh.14085. Epub 2016 May 10.

34.

Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.

Desai AV, Heneghan MB, Li Y, Bunin NJ, Grupp SA, Bagatell R, Seif AE.

Bone Marrow Transplant. 2016 Sep;51(9):1204-10. doi: 10.1038/bmt.2016.84. Epub 2016 May 9.

PMID:
27159174
35.

Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States.

DiNofia AM, Salazar E, Seif AE, Li Y, Huang YS, Bagatell R, Fisher BT, Aplenc R.

PLoS One. 2016 Mar 15;11(3):e0151362. doi: 10.1371/journal.pone.0151362. eCollection 2016.

36.

Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.

Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R.

J Clin Oncol. 2016 May 1;34(13):1537-43. doi: 10.1200/JCO.2015.65.5860. Epub 2016 Feb 16.

37.

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP.

J Clin Oncol. 2016 Apr 20;34(12):1368-75. doi: 10.1200/JCO.2015.65.4889. Epub 2016 Feb 16.

38.

Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.

Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL.

Pediatr Blood Cancer. 2016 Jun;63(6):1019-23. doi: 10.1002/pbc.25934. Epub 2016 Feb 10.

39.

Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.

Desai AV, Seif AE, Li Y, Getz K, Fisher BT, Huang V, Mante A, Aplenc R, Bagatell R.

Pediatr Blood Cancer. 2016 May;63(5):901-7. doi: 10.1002/pbc.25893. Epub 2016 Jan 21.

40.

Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study.

Bagatell R, McHugh K, Naranjo A, Van Ryn C, Kirby C, Brock P, Lyons KA, States LJ, Rojas Y, Miller A, Volchenboum SL, Simon T, Krug B, Sarnacki S, Valteau-Couanet D, von Schweinitz D, Kammer B, Granata C, Pio L, Park JR, Nuchtern J.

J Clin Oncol. 2016 Mar 1;34(7):740-6. doi: 10.1200/JCO.2015.63.2042. Epub 2016 Jan 11.

41.

A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.

Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R.

Leuk Lymphoma. 2016 Jul;57(7):1567-74. doi: 10.3109/10428194.2015.1088652. Epub 2016 Jan 4.

42.

Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group.

Li Y, Hall M, Fisher BT, Seif AE, Huang YS, Bagatell R, Getz KD, Alonzo TA, Gerbing RB, Sung L, Adamson PC, Gamis A, Aplenc R.

PLoS One. 2015 Nov 25;10(11):e0143480. doi: 10.1371/journal.pone.0143480. eCollection 2015.

43.

Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia.

Lee GE, Fisher BT, Xiao R, Coffin SE, Feemster K, Seif AE, Bagatell R, Li Y, Huang YS, Aplenc R.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):290-6. doi: 10.1093/jpids/piu066. Epub 2014 Jul 22.

44.

Genetic discoveries and treatment advances in neuroblastoma.

Bagatell R, Cohn SL.

Curr Opin Pediatr. 2016 Feb;28(1):19-25. doi: 10.1097/MOP.0000000000000296. Review.

45.

A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia.

Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Bagatell R, Fisher BT, Aplenc R.

Cancer Med. 2015 Sep;4(9):1356-64. doi: 10.1002/cam4.481. Epub 2015 Jun 24.

46.

Suspected posaconazole toxicity in a pediatric oncology patient.

Martino J, Fisher BT, Bosse KR, Bagatell R.

Pediatr Blood Cancer. 2015 Sep;62(9):1682. doi: 10.1002/pbc.25568. Epub 2015 May 6. No abstract available.

47.

Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.

Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R.

Pediatr Blood Cancer. 2015 Oct;62(10):1775-81. doi: 10.1002/pbc.25569. Epub 2015 May 6.

48.

Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.

Miller TP, Troxel AB, Li Y, Huang YS, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R.

Pediatr Blood Cancer. 2015 Jul;62(7):1184-9. doi: 10.1002/pbc.25475. Epub 2015 Mar 11.

49.

A rapid progression of disease after surgical excision of a malignant rhabdoid tumor of the bladder.

Sterling ME, Long CJ, Bosse KR, Bagatell R, Shukla AR.

Urology. 2015 Mar;85(3):664-6. doi: 10.1016/j.urology.2014.11.011. Epub 2015 Jan 9.

50.

Mechanisms of neuroblastoma regression.

Brodeur GM, Bagatell R.

Nat Rev Clin Oncol. 2014 Dec;11(12):704-13. doi: 10.1038/nrclinonc.2014.168. Epub 2014 Oct 21. Review.

Supplemental Content

Loading ...
Support Center